MYIA
CGTX icon

Mount Yale Investment Advisors’s Cognition Therapeutics CGTX Stock Holding History

Mount Yale Investment Advisors’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.63K Buy
+10,040
New +$11.7K ﹤0.01% 1095

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Mount Yale Investment Advisors's CGTX Position: Q1 2026 in Review

Mount Yale Investment Advisors opened a new position in Cognition Therapeutics (CGTX) in Q1 2026: 10,040 shares worth $7.63K. The stake represents ﹤0.01% of the portfolio and ranks #1095 among its holdings.

75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Mount Yale Investment Advisors held 10,040 shares of Cognition Therapeutics worth $7.63K as of Q1 2026.
  • Cognition Therapeutics was a new Mount Yale Investment Advisors position in Q1 2026.
  • Cognition Therapeutics made up ﹤0.01% of Mount Yale Investment Advisors's portfolio in Q1 2026, its #1095 holding.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.